Ocugen, a biotech company specializing in gene therapies for blindness, announced it will present its innovative modifier gene therapy platform at two investor conferences in August 2026. The presentations will include a panel discussion at the Oppenheimer Biotech Summit and a fireside chat at the Canaccord Growth Conference. Ocugen's gene-agnostic therapy aims to treat multiple blindness diseases by addressing underlying disease biology rather than single gene mutations. This exposure could boost investor awareness as the company advances treatments for inherited retinal diseases and age-related macular degeneration.
Halper Sadeh LLC is investigating whether officers and directors of iRhythm Technologies breached their fiduciary duties to shareholders. Long-term iRhythm stockholders may seek reforms, financial incentives, or other relief if misconduct is found. T...
Bitcoin hovered close to $63,000 with minor fluctuations, as traders watched critical support at $62,200 and resistance near $63,400. Market experts predict volatile trading until Bitcoin decisively breaks above $65,000, which could trigger stronger ...
Cybercriminals exploited a critical vulnerability in macOS Screen Sharing to gain root access and deploy Monero mining malware on exposed Macs. The Dutch National Cyber Security Centre confirmed active attacks targeting systems with port 5900 open on...
Halper Sadeh LLC is investigating whether MongoDB's officers and directors breached their fiduciary duties to shareholders. Long-term MongoDB stockholders may be eligible to seek corporate governance reforms, financial incentives, or other relief. Th...
Halper Sadeh LLC is investigating whether certain officers and directors of WEBTOON Entertainment Inc. violated their fiduciary duties to shareholders. Long-term WEBTOON stockholders may seek corporate governance reforms, financial incentives, or oth...
